N | NF-κB p65 expression | |||
---|---|---|---|---|
negative | positive | |||
3+3=6 | 123 | 103 | 20 | |
3+4=7 | 30 | 24 | 6 | 0.596* |
4+3=7 | 30 | 17 | 13 | 0.003** |
Hazard ratio (95% CI) | ||
---|---|---|
NF-(negative κB p65 expression | 0.254 (0.034–1.915) | 0.184 |
Postoperative score (6 | 1.078 (0.400–2.907) | 0.882 |
Surgical (negative margin | 4.838 (1.674–13.983) | 0.004 |
Pathologic (T2 | 1.232 (0.409–3.705) | 0.711 |
N = 123 | N | NF-κB p65 expression | ||
---|---|---|---|---|
negative | positive | |||
pT status | ||||
pT2 | 96 | 48 | 48 | |
pT3 | 27 | 12 | 15 | 0.667* |
Surg. m. | ||||
Negative | 110 | 53 | 7 | |
Positive | 13 | 7 | 6 | 0.774** |
GS | ||||
3 + 3 = 6 | 79 | 39 | 40 | |
3 + 4 = 7 | 37 | 17 | 20 | |
4 + 3 = 7 | 7 | 5 | 2 | 0.465*** |
N = 123 | N | NF-κB p65 expression | ||
---|---|---|---|---|
negative | positive | |||
pT status | ||||
pT2 | 96 | 81 | 15 | |
pT3 | 27 | 22 | 5 | 0.769* |
Surg. m. | ||||
Negative | 110 | 92 | 18 | |
Positive | 13 | 11 | 2 | 1** |
GS | ||||
3 + 3 = 6 | 79 | 66 | 13 | |
3 + 4 = 7 | 37 | 31 | 6 | |
4 + 3 = 7 | 7 | 6 | 1 | 0.989*** |
Hazard ratio (95% CI) | P | |
---|---|---|
Cytoplasmic NF-κB p65 expression (negative | 2.367 (0.908–6.170) | 0.078 |
Postoperative Gleason score (6 | 1.105 (0.406–3.008) | 0.845 |
Surgical (negative margin | 4.845 (1.646–14.260) | 0.004 |
Pathologic (T2 | 1.041 (0.339–3.194) | 0.944 |
N | NF-κB p65 expression | |||
---|---|---|---|---|
negative | positive | |||
3 + 3 = 6 | 123 | 60 | 63 | |
3 + 4 = 7 | 30 | 3 | 27 | <0.001* |
4 + 3 = 7 | 30 | 0 | 30 | <0.001** |
General, N = 123 | |||
---|---|---|---|
Mean Age, | 63.6 (50–75) | ||
Mean init. PSA, | 5.32 (1,32–9,51) | ||
Mean Prostate V, | 38.3 (14–97) | ||
Mean Biopsy cores, | 9.6 (8–10) | ||
Total Biopsy | 1.180 | ||
Clinical stage | |||
T1, | 113 (91.9) | ||
T2, | 10 (8.1) | ||
Biopsy GS 3+3=6, | 123 (100) | ||
Surgery | |||
ELRP, | 87 (70.7) | ||
N-S ELRP, | 36 (29.3) |